clinical trial · NCT06875986
REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
Otsuka Pharmaceutical Co., Ltd.·—·recruiting·n = 200
Alzheimer DiseaseBrexpiprazole (Rexulti)
brief summary
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
started
Apr 17, 2025
primary completion
Sep 30, 2027
completion
Sep 23, 2028
last updated
Jul 2, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol